Pierce, Marquicia R <br/><br/>
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.  [electronic resource] 

 -  Leukemia research  01 2020 
 - 106271 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2019.106271  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amides--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Azoles--administration & dosage<br/>Bortezomib--administration & dosage<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Humans<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Mice, Transgenic<br/>Multiple Myeloma--drug therapy<br/>Peptides, Cyclic--chemistry<br/>Proteasome Inhibitors--administration & dosage<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays